Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

529832

	registered interest
	date	29/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Surgery: Waiting Lists
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to minimise the number of cancelled operations caused by bed shortages.
	tabling member constituency	Leeds West
	tabling member printed	Rachel Reeves
	uin	41491
	answer	answer is ministerial correction date of answer 04/07/2016 answer text <p>NHS England publishes each quarter at the following link the number of elective operations cancelled by hospitals for non-clinical reasons on or after the day of admission:</p><p> </p><p><a href="https://www.england.nhs.uk/statistics/statistical-work-areas/cancelled-elective-operations/cancelled-ops-data/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/cancelled-elective-operations/cancelled-ops-data/</a></p><p> </p><p>The reasons for the cancellations are not collected.</p><p> </p><p>The National Health Service should do everything it can to reduce cancellations and keep them to an absolute minimum. Where this is unavoidable, patients should receive treatment as soon as possible. This is reinforced by a pledge in the NHS Constitution for all patients who have operations cancelled, on or after the day of admission (including the day of surgery), for non-clinical reasons to be offered another binding date within 28 days, or the patient’s treatment to be funded at the time and hospital of the patient’s choice.</p><p> </p><p>The number of cancelled elective operations as a percentage of admissions has remained at less than 1% in each of the last 10 years.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 41492 question first answered 04/07/2016 15:50:01 answering member 4020 label Biography information for George Freeman
	tabling member	4031 label Biography information for Rachel Reeves

529833

	registered interest
	date	29/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Surgery: Waiting Lists
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many cancelled operations were caused by bed shortages in each of the last five years.
	tabling member constituency	Leeds West
	tabling member printed	Rachel Reeves
	uin	41492
	answer	answer is ministerial correction date of answer 04/07/2016 answer text <p>NHS England publishes each quarter at the following link the number of elective operations cancelled by hospitals for non-clinical reasons on or after the day of admission:</p><p> </p><p><a href="https://www.england.nhs.uk/statistics/statistical-work-areas/cancelled-elective-operations/cancelled-ops-data/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/cancelled-elective-operations/cancelled-ops-data/</a></p><p> </p><p>The reasons for the cancellations are not collected.</p><p> </p><p>The National Health Service should do everything it can to reduce cancellations and keep them to an absolute minimum. Where this is unavoidable, patients should receive treatment as soon as possible. This is reinforced by a pledge in the NHS Constitution for all patients who have operations cancelled, on or after the day of admission (including the day of surgery), for non-clinical reasons to be offered another binding date within 28 days, or the patient’s treatment to be funded at the time and hospital of the patient’s choice.</p><p> </p><p>The number of cancelled elective operations as a percentage of admissions has remained at less than 1% in each of the last 10 years.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 41491 question first answered 04/07/2016 15:50:01 answering member 4020 label Biography information for George Freeman
	tabling member	4031 label Biography information for Rachel Reeves

529278

	registered interest
	date	28/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will bring forward regulations to prevent drug manufacturers excessively raising the cost of drugs to the NHS when they are the sole or dominant supplier.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	41350
	answer	answer is ministerial correction date of answer 04/07/2016 answer text <p>The Department is already referring cases to the Competition and Markets Authority (CMA). To strengthen our work in this area we are considering putting measures in place to routinely and systematically monitor significant price increases of generic medicines and take action where appropriate, including the possible referral of suspected excessive pricing to the CMA, while taking into account the potential impact of any such action on the availability of medicines.</p><p> </p><p>The CMA is currently conducting a number of investigations into anti-competitive practices in the pharmaceutical industry. It imposed fines totalling £45 million in one case (currently subject to appeal at the Competition Appeal Tribunal), and expects to reach a final decision by late summer in another. It opened two more cases in March and April 2016 in which it expects to decide in late summer whether there are grounds to take each investigation further.</p><p> </p><p>The CMA is also considering evidence of other potential cases of anti-competitive practices in the sector, and may well open further investigations in the coming months.</p><p> </p><p>The CMA is independent of Ministers and we cannot interfere in either the substance or the procedures of its decision-making.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 41353 question first answered 04/07/2016 15:41:29 answering member 4020 label Biography information for George Freeman
	tabling member	298 label Biography information for Steve McCabe

529279

	registered interest
	date	28/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Drugs: Competition
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when he expects the Competition and Markets Authority to report on its investigation on suspected anti-competitive practices in the pharmaceutical sector.
	tabling member constituency	Birmingham, Selly Oak
	tabling member printed	Steve McCabe
	uin	41353
	answer	answer is ministerial correction date of answer 04/07/2016 answer text <p>The Department is already referring cases to the Competition and Markets Authority (CMA). To strengthen our work in this area we are considering putting measures in place to routinely and systematically monitor significant price increases of generic medicines and take action where appropriate, including the possible referral of suspected excessive pricing to the CMA, while taking into account the potential impact of any such action on the availability of medicines.</p><p> </p><p>The CMA is currently conducting a number of investigations into anti-competitive practices in the pharmaceutical industry. It imposed fines totalling £45 million in one case (currently subject to appeal at the Competition Appeal Tribunal), and expects to reach a final decision by late summer in another. It opened two more cases in March and April 2016 in which it expects to decide in late summer whether there are grounds to take each investigation further.</p><p> </p><p>The CMA is also considering evidence of other potential cases of anti-competitive practices in the sector, and may well open further investigations in the coming months.</p><p> </p><p>The CMA is independent of Ministers and we cannot interfere in either the substance or the procedures of its decision-making.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 41350 question first answered 04/07/2016 15:41:29 answering member 4020 label Biography information for George Freeman
	tabling member	298 label Biography information for Steve McCabe

528600

	registered interest
	date	24/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Sherwood Forest Hospitals NHS Foundation Trust
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions his Department has had in recent months with (a) Sherwood Forest Hospitals NHS Foundation Trust and (b) Nottingham University Hospitals Trust on potential financial support from his Department to cover the costs of Sherwood Forest's PFI arrangements.
	tabling member constituency	Ashfield
	tabling member printed	Gloria De Piero
	uin	41186
	answer	answer is ministerial correction date of answer 04/07/2016 answer text <p>The Department has not received an application for Private Finance Iinitiative financial support associated with the proposed Sherwood Forest Hospitals NHS Foundation Trust and Nottingham University Hospitals NHS Trust long term partnership.</p><p> </p><p>The Department has taken part in a brief initial discussion with Nottingham University Hospital NHS Trust’s advisors and NHS Improvement in relation to the process, timescales and other relevant issues associated with the long term partnership. However financial plans for the long term partnership have not yet been put forward to the Department to enable formal financial discussions.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/07/2016 15:37:19 answering member 4020 label Biography information for George Freeman
	tabling member	3915 label Biography information for Gloria De Piero

528612

	registered interest
	date	24/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Drugs: Prices
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what plans he has to bring forward proposals for a change to legislation to further regulate the pricing of everyday drugs to the NHS by pharmaceutical companies.
	tabling member constituency	Leicester East
	tabling member printed	Keith Vaz
	uin	41132
	answer	answer is ministerial correction date of answer 04/07/2016 answer text <p>The Department is already referring cases to the Competition and Market Authority (CMA) and to strengthen our work in this area. We are considering putting measures in place to routinely and systematically monitor significant price increases of generic medicines and take action where appropriate, including the possible referral of suspected excessive pricing to the CMA, while taking into account the potential impact of any such action on the availability of medicines.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/07/2016 15:38:09 answering member 4020 label Biography information for George Freeman
	tabling member	338 label Biography information for Keith Vaz

528613

	registered interest
	date	24/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Blood Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the (a) treatment targets and (b) care processes are for people with (i) sickle cell disease and (ii) thalassaemia in each (A) clinical commissioning group area, (B) trust area and (C) national sickle cell and thalassaemia centre area in the most recent year for which figures are available.
	tabling member constituency	Hackney North and Stoke Newington
	tabling member printed	Ms Diane Abbott
	uin	41133
	answer	answer is ministerial correction date of answer 04/07/2016 answer text <p>NHS England has a published service specification for haemoglobinopathy which covers the requirements of commissioned services providing specialised services for patients with sickle cell disease or thalassaemia. The specification was developed by the Haemoglobinopathies Clinical Reference Group that covers Sickle Cell Disease, Thalassaemia and other very rare anaemias requiring lifelong transfusion and chelation. The specification reflects that although these are complex disorders they are often grouped together and managed by the same specialist team. It recognises that each condition will have distinct clinical manifestations and treatments.</p><p> </p><p>Specialised services for haemoglobinopathy care B08/S/a:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b08-speci-serv-haemo.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b08-speci-serv-haemo.pdf</a></p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/07/2016 15:33:16 answering member 4020 label Biography information for George Freeman
	tabling member	172 label Biography information for Ms Diane Abbott

528614

	registered interest
	date	24/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Blood Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate he has made of the proportion of people from black, Asian and minority ethnic communities who have received a diagnosis of (a) sickle cell disease and (b) thalassaemia in each (i) clinical commissioning group area, (ii) trust area and (iii) national sickle cell and thalassaemia centre area; and what proportion of people from such communities were so diagnosed in the most recent year for which figures are available.
	tabling member constituency	Hackney North and Stoke Newington
	tabling member printed	Ms Diane Abbott
	uin	41134
	answer	answer is ministerial correction date of answer 04/07/2016 answer text <p>The National Haemoglobinopathy Registry maintains a database of patients with red cell disorders (mainly sickle cell disease and thalassaemia major) living in the United Kingdom. Detailed information on the number of patients diagnosed with sickle cell disease and thalassaemia, in England, is available from the National Haemoglobinopathy Registry Report 2013/14. This includes a breakdown of patients on the basis ethnicity, commissioning hub and specialist treatment centre.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/07/2016 15:29:02 answering member 4020 label Biography information for George Freeman
	tabling member	172 label Biography information for Ms Diane Abbott

528615

	registered interest
	date	24/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Blood
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many apheresis machines are operational in the UK; and where those machines are located.
	tabling member constituency	Hackney North and Stoke Newington
	tabling member printed	Ms Diane Abbott
	uin	41135
	answer	answer is ministerial correction date of answer 04/07/2016 answer text <p>Apheresis machines are part of the care provided in a number of haematology services including sickle cell and thalassaemia care.</p><p> </p><p>NHS Blood and Transplant is one of the main providers of Therapeutic Apheresis Services in England and has the largest installed base of therapeutic apheresis equipment in the National Health Service (32 machine platforms across the country). Additional provision of apheresis services are provided by NHS trusts and other UK Blood Services but NHS England does not currently hold information on this information centrally.</p><p> </p><p>Work in relation to these services including the incentivisation of automated exchange through Commissioning for Quality and Innovation will improve the baseline information over the coming year.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/07/2016 15:35:17 answering member 4020 label Biography information for George Freeman
	tabling member	172 label Biography information for Ms Diane Abbott

528616

	registered interest
	date	24/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Blood Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many people have died as a result of (a) sickle cell disease and (b) thalassaemia in each (i) clinical commissioning group area, (ii) trust area and (iii) national sickle cell and thalassaemia centre area in the most recent year for which figures are available.
	tabling member constituency	Hackney North and Stoke Newington
	tabling member printed	Ms Diane Abbott
	uin	41136
	answer	answer is ministerial correction date of answer 04/07/2016 answer text <p>NHS England does not routinely collect this information. Data on adverse events for patients with sickle cell disease and thalassaemia is available from the National Haemoglobinopathy Registry Report 2013/14.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/07/2016 15:34:23 answering member 4020 label Biography information for George Freeman
	tabling member	172 label Biography information for Ms Diane Abbott